Isodiol International Inc. Applauds the FDA’s Decision to Recognize the Medical Benefits of CBD at Higher Concentrations an...
June 27 2018 - 9:41AM
Isodiol International Inc. (
CSE:
ISOL)
(
OTC:
ISOLF)
(
FSE: LB6A.F)
(the “Company” or “Isodiol”), a global CBD
innovator specializing in hemp-based health and wellness products,
the development of pharmaceutical CBD delivery methods and the
manufacturing of a pure, natural CBD as an Active Pharmaceutical
Ingredient (API) for use in finished pharmaceutical products
(FPPs), applauds the FDA’s decision on the long-anticipated
approval of GW Pharmaceutical’s (NASDAQ: GWPH) Epidiolex for the
treatment of seizures associated with two forms of epilepsy.
“Fundamentally, the approval of Epidiolex will have no legal
impact on the sale of hemp-derived CBD for consumer goods.
The fact that the FDA has stated that they will focus on
proliferation and illegal marketing of unapproved CBD-containing
products with unproven medical claims is welcomed by Isodiol,
stated Marcos Agramont, Isodiol International, Inc. CEO.”
The company believes the FDA’s decision adds value to its
Approved Pharmaceutical Ingredient (API) for finished
pharmaceutical products (FPP). Much like GWPH's product that went
through this extensive approval process, Isodiol can supply those
interested in developing finished pharmaceutical products or
conducting clinical research studies with Cannabidiol CBD the
option to utilize Isodiol's API to save time and money.
Given that the FDA’s approval of Epidiolex raises the visibility
of hemp-derived CBD products, it is even more critical that the
U.S. Congress passes the Hemp Farming Act to permanently establish
hemp and hemp-derived products as agricultural commodities in the
United States. Isodiol encourages supporters of hemp and
hemp-derived CBD to use the U.S. Hemp Roundtable’s web portal to
contact their Congressmen today and urge them to support the
passage of the Hemp Farming Act. CLICK HERE to send a letter
to your U.S. Senators.
To better situate the Company for future growth and expansion
and to maximize shareholder value, the Company intends to
consolidate its issued and outstanding ordinary share capital
(“Common Shares”) on the basis of a one (1) post-consolidated
Common Share for each (10) pre-consolidation Common Shares (the
“Consolidation”). As a result, the outstanding Common Shares of the
Company will be reduced to approximately 40 million Common
Shares.
This Consolidation is being completed with the intention of an
up listing to a major exchange in the United States which will give
the Company access to more US based retail and institutional
investors. The up listing will provide the company the ability to
maximize growth and capitalize on new opportunities from the
developments surrounding the FDA’s recent approval and stance on
CBD based medicines as well as new opportunities arising from the
anticipated approval of the Agricultural Improvement Act of 2018
that is expected to legalize hemp as an agricultural product in the
United States.
The Consolidation is subject to the approval of the Canadian
Securities Exchange, and it is anticipated that the Consolidation
will be implemented in the month of July 2018.
For more information on Isodiol, please visit
www.isodiol.com
About Isodiol International
Inc.
Isodiol International Inc. is
the market leader in pharmaceutical grade pure, natural CBD and the
industry leader in the manufacturing and development of CBD
consumer products.
Isodiol is the pioneer of many firsts in the CBD
industry, including the commercialization of 99%+ pure, natural
isolated CBD, micro-encapsulations, and nano-technology for the
highest quality consumable and topical skin care products. Most
recently, the company received approval for its CBD designated as
an Active Pharmaceutical Ingredient for use in Finished
Pharmaceutical Products as was announced April 26, 2018.
Isodiol’s growth strategy includes the
development of over-the-counter and pharmaceutical drugs, expanding
its consumer products portfolio and aggressively continue
international expansion into Latin America, Asia, and Europe.
Join Us On Facebook:
https://www.facebook.com/IsodiolInternationalInc/Twitter:
@Isodiolintlinc
ON BEHALF OF THE BOARDMarcos
Agramont, CEO & Director
INVESTOR
RELATIONS:Ir@isodiol.comwww.isodiol.com
Forward-Looking Information:
This news release contains "forward-looking information" within the
meaning of applicable securities laws relating to statements
regarding the Company's business, products and future the Company’s
business, its product offerings and plans for sales and marketing.
Although the Company believes that the expectations reflected in
the forward-looking information are reasonable, there can be no
assurance that such expectations will prove to be correct. Readers
are cautioned not to place undue reliance on forward-looking
information. Such forward-looking statements are subject to risks
and uncertainties that may cause actual results, performance and
developments to differ materially from those contemplated by these
statements depending on, among other things, the risks that the
Company's products and plan will vary from those stated in this
news release and the Company may not be able to carry out its
business plans as expected. Except as required by law, the Company
expressly disclaims any obligation and does not intend, to update
any forward-looking statements or forward-looking information in
this news release. Although the Company believes that the
expectations reflected in the forward-looking information are
reasonable, there can be no assurance that such expectations will
prove to be correct and makes no reference to profitability based
on sales reported. The statements in this news release are made as
of the date of this release.
The CSE has not reviewed, approved or disapproved
the content of this press release.
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Apr 2023 to Apr 2024